Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 8/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.43 |
| ▸ | FLT3 | P36888 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041609 | 0.80 | PRMT5 (0.42) | PRMT5WDR77FLT3RET | |
| SCHEMBL2263881 | 0.79 | FLT3 (0.47) | PRMT5WDR77FLT3 | |
| Hydrochloric Acid SCHEMBL4032782 | 0.78 | FLT3 (0.46) | PRMT5WDR77FLT3 | |
| SCHEMBL2261411 | 0.76 | PRMT5 (0.40) | PRMT5WDR77KDRPARP1 | |
| SCHEMBL3832037 | 0.71 | CYP1A2 (0.43) | PRMT5WDR77FLT3HPGDPARP1 | |
| SCHEMBL10174894 | 0.69 | KDR (0.71) | PRMT5WDR77KDRFGFR3FLT3 | |
| SCHEMBL16964942 | 0.68 | KDR (0.64) | PRMT5WDR77KDRFGFR3FLT3 | |
| SCHEMBL3031962 | 0.68 | KDR (0.51) | PRMT5WDR77KDRFGFR3FLT3 | |
| SCHEMBL23104850 | 0.68 | MAP4K1 (0.46) | PRMT5WDR77 | |
| SCHEMBL2261834 | 0.68 | CDK8 (0.50) | KDRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491716-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | PNP, ADK, NME2 | PRMT5 809/4885WDR77 1243/4885KDR 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.